Pharmaceuticals, Biotechnology and Life Sciences
First disclosure of PRT12396, a JAK2V617F-selective JH2 inhibitor demonstrates disease modifying potential in myeloproliferative neoplasms PRT12396 has completed GLP toxicology…
Lisaftoclax monotherapy demonstrated significant and durable clinical efficacy and a manageable safety profile in patients with heavily pretreated BTK-refractory R/R…
Follow-up data from CARTITUDE-4 show at least 80 percent of as-treated standard-risk patients remained progression- and treatment-free following a single…
— Bezuclastinib achieves clear clinical benefit across all symptom domains including significant improvements on 11 individual symptoms plus the most…
Objective response rate (ORR) of 83% including two complete responses in CLL patients in Phase 1a study with median progression…
Phase 2 results selected as one of only 10 featured presentations in the Poster Tour at the 2025 Parkinson Study…
Highly differentiated 1L preliminary systemic activity of 67% ORR and 100% intracranial ORR (by BICR-RANO), including in patients with active…
San Diego, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) — Sapu Nano today announced new biomarker data identifying a molecular signature…
Highly differentiated 1L EGFR PACC preliminary systemic activity of 80% ORR and 100% intracranial ORR, including in patients with active…
Data showed encouraging results in patients with higher CLDN18.2 expression regardless of PD-L1 expression level, with a median PFS of…